Skip to main content
. 2022 Apr 21;65(7):1085–1097. doi: 10.1007/s00125-022-05694-6

Fig. 3.

Fig. 3

Effects of dapagliflozin on the primary composite outcomes across KDIGO risk categories and subgroups of UACR and eGFR in patients with diabetes (a) and without diabetes (b). The primary composite outcome is a composite of an eGFR decline of ≥50%, ESKD or death from kidney or cardiovascular causes